Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023
18 Octobre 2023 - 10:05PM
Business Wire
– Conference Call and Webcast to Follow at 5:00
p.m. ET / 2:00 p.m. PT –
Exelixis, Inc. (Nasdaq: EXEL) announced today that its third
quarter 2023 financial results will be released on Wednesday,
November 1, 2023 after the markets close. At 5:00 p.m. ET / 2:00
p.m. PT, Exelixis management will host a conference call and
webcast to discuss the results and provide a general business
update. Access to the event is available via the Internet from the
company’s website.
To access the conference call, please register using this link.
Upon registration, a dial-in number and unique PIN will be provided
to join the call. To access the live webcast link, log onto
www.exelixis.com and proceed to the Event Calendar page under the
Investors & News heading. Please connect to the company’s
website at least 15 minutes prior to the conference call to ensure
adequate time for any software download that may be required to
listen to the webcast. A webcast replay of the conference call will
also be archived on www.exelixis.com for one year.
About Exelixis
Exelixis is a globally ambitious oncology company innovating
next-generation medicines and regimens at the forefront of cancer
care. Powered by bi-coastal centers of discovery and development
excellence, we are rapidly evolving our product portfolio to target
an expanding range of tumor types and indications with our
clinically differentiated pipeline of small molecules,
antibody-drug conjugates and other biotherapeutics. This
comprehensive approach harnesses decades of robust investment in
our science and partnerships to advance our investigational
programs and extend the impact of our flagship commercial product,
CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific
pursuit to create transformational treatments that give more
patients hope for the future. For information about the company and
its mission to help cancer patients recover stronger and live
longer, visit www.exelixis.com, follow @ExelixisInc on Twitter,
like Exelixis, Inc. on Facebook and follow Exelixis on
LinkedIn.
Exelixis, the Exelixis logo and CABOMETYX are
registered U.S. trademarks.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231018651780/en/
Investors Contact: Varant Shirvanian Associate Director,
Investor Relations Exelixis, Inc. 650-837-8194
vshirvanian@exelixis.com
Media Contact: Hal Mackins For Exelixis, Inc.
415-994-0040 hal@torchcommunications.com
Exelixis (NASDAQ:EXEL)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Exelixis (NASDAQ:EXEL)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024